BeOne Medicines Ltd. (06160) has reached an agreement with the United States to expand the accessibility of innovative oncology drugs.

BeOne Medicines Ltd. (06160) announced today that it has voluntarily reached an agreement with the U.S. government aimed at helping more eligible patients access innovative drug treatments. According to public information, the other eight companies involved in the arrangement include Alcon, Astellas Pharma, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB. Under the agreement, BeOne Medicines Ltd. will provide taletrectinib to eligible patients through the Medicaid program at an agreed-upon price. Medicaid is a U.S. healthcare program aimed at specific eligible populations, covering qualified children, pregnant women, the elderly, individuals with disabilities, and some vulnerable groups, many of whom may face challenges related to the burden of healthcare services. It is expected that the patient population benefiting from this agreement will represent approximately 8% of the patient population in the U.S. approved indications for Bai Ze An. The company stated that this voluntary agreement is a market-specific arrangement made in consideration of the local healthcare payment system and policy environment, aiming to further enhance the accessibility of innovative drugs and benefit more eligible patients. Bai Ze An is the cornerstone drug in BeOne Medicines Ltd.'s oncology portfolio, and the company will continue to work towards benefiting more patients globally. To date, Bai Ze An has been approved in over 50 markets worldwide and has benefited more than 2 million patients; in China, 13 indications have been included in the national medical insurance drug catalog. Meanwhile, as more combination therapy solutions are continuously explored, the clinical application prospects of Bai Ze An are continuously expanding. BeOne Medicines Ltd. is committed to a patient-centered approach, collaborating with local stakeholders to promote innovative drugs in ways that are suitable for local healthcare systems, policy environments, and patient needs.